title: ABT-737 synergizes with Bortezomib to kill melanoma cells.
abstract: The BH3 mimetic ABT-737 is a potent inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L), and Bcl-w. The Bcl-2 family modulates sensitivity to anticancer drugs in many cancers, including melanomas. In this study, we examined whether ABT-737 is effective in killing melanoma cells either alone or in combination with a proteasome inhibitor already in clinical use (Bortezomib) in vitro and in vivo, and further evaluated the mechanisms of action. Results showed that ABT-737 alone induced modest cytotoxicity in melanoma cells, but only at higher doses. Knock-down of the anti-apoptotic proteins Bcl-2, Bcl-X(L), or Mcl-1 with siRNAs demonstrated that Mcl-1 is the critical mediator of melanoma's resistance to ABT-737 treatment. However, ABT-737 displayed strong synergistic lethality when combined with Bortezomib. Immunoblot analyses demonstrated that Bortezomib increased expression of Noxa, a pro-apoptotic Bcl-2 member that antagonizes Mcl-1. Additionally, siRNA-mediated inhibition of Noxa expression protected melanoma cells from cytotoxicity induced by the combination treatment. These results demonstrate that Bortezomib synergizes with ABT-737 by neutralizing Mcl-1's function via increased levels of Noxa. In a xenograft mouse model, although drug doses were limited due to toxicity, ABT-737 or Bortezomib slowed melanoma tumor growth compared to the control, and the drug combination significantly decreased growth compared to either drug alone. These data imply that less toxic drugs fulfilling a function similar to Bortezomib to neutralize Mcl-1 are promising candidates for combination with ABT-737 for treating melanomas.
authors.affiliation: University of Colorado Denver, School of Medicine, Department of Dermatology ,  Aurora, CO 80045, USA.
authors.forename: Steven N
authors.initials: SN
authors.lastname: Reuland
authors.forename: Nathaniel B
authors.initials: NB
authors.lastname: Goldstein
authors.forename: Katie A
authors.initials: KA
authors.lastname: Partyka
authors.forename: Shilo
authors.initials: S
authors.lastname: Smith
authors.forename: Yuchun
authors.initials: Y
authors.lastname: Luo
authors.forename: Mayumi
authors.initials: M
authors.lastname: Fujita
authors.forename: Rene
authors.initials: R
authors.lastname: Gonzalez
authors.forename: Karl
authors.initials: K
authors.lastname: Lewis
authors.forename: David A
authors.initials: DA
authors.lastname: Norris
authors.forename: Yiqun G
authors.initials: YG
authors.lastname: Shellman